STOCK TITAN

Surrozen Inc - SRZN STOCK NEWS

Welcome to our dedicated page for Surrozen news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.

Overview

Surrozen Inc (SRZN) is a clinical-stage biotechnology company devoted to the discovery and development of innovative regenerative medicines that harness the power of the body’s natural repair mechanisms. Utilizing advanced tissue-specific antibody platforms, the company focuses on modulating the Wnt signaling pathway, a critical mediator in tissue repair and regeneration, to create novel therapeutics for severe liver and ocular diseases. With a solid foundation in cutting-edge research, Surrozen has built its expertise from the work of its founding scientists, who bring extensive experience from prestigious academic institutions.

Core Therapeutic Focus

The company’s core approach is centered on Wnt pathway modulation for tissue regeneration. Surrozen is actively developing drug candidates designed to selectively enhance Wnt signaling, facilitating effective tissue repair in conditions that traditionally have limited treatment options. By strategically targeting the pathway, the company addresses regenerative needs in organs such as the liver and retina, thereby opening avenues for novel therapeutic interventions in diseases like severe alcohol-associated hepatitis, retinal vascular disorders, and ocular degenerative conditions.

Innovative Technology Platforms

Surrozen leverages proprietary antibody platforms including SWEETS and SWAP, which are engineered to mimic and enhance the natural activities of Wnt proteins. These approaches enable the creation of bispecific antibodies that can precisely activate the Wnt pathway in targeted tissues. This specificity is critical for minimizing off-target effects while maximizing regenerative outcomes, and it underscores the company’s commitment to developing therapies that are both innovative and safe.

Operational and Clinical Excellence

Currently in the clinical phase, Surrozen’s robust pipeline includes multiple drug candidates undergoing or advancing through early phase clinical trials. These studies are designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamic responses, with early data demonstrating acceptable safety profiles and evidence of target engagement. The clinical programs underscore a methodical approach to drug development, reflecting deep expertise in designing trials that address unmet medical needs.

Strategic Market Position

In a competitive biotechnology landscape, Surrozen distinguishes itself through its scientific rigor and specialized focus on regenerative mechanisms. The company’s reliance on advanced antibody engineering and precise modulation of the Wnt pathway positions it uniquely in the drug development arena. By focusing on clear clinical endpoints and leveraging partnerships with established industry leaders, Surrozen reinforces its credibility and authority as it seeks to provide transformative solutions in the treatment of severe liver and retinal diseases.

Industry and Scientific Relevance

Surrozen’s activities resonate deeply within the biotechnology sector, where the understanding and manipulation of critical signaling pathways remain central to therapeutic innovation. The company’s approach is backed by extensive research and development, making it a valuable source of expertise regarding the subset of therapeutics that employ regenerative and tissue-specific antibody modalities. Its scientific publications and strategic collaborations further underscore the company’s contribution to advancing the field of regenerative medicine.

Conclusion

Overall, Surrozen Inc exemplifies the modern clinical-stage biotechnology firm: dedicated to unlocking complex biological processes through state-of-the-art antibody engineering and focused on addressing significant unmet clinical needs. Its in-depth knowledge of the Wnt pathway and commitment to regenerative medicine underscore a strategy built on scientific innovation and methodological rigor, making Surrozen a vital point of reference for investors and stakeholders seeking comprehensive insights into cutting-edge therapeutic development.

Rhea-AI Summary

Surrozen (SRZN) reported its Q4 and full year 2024 financial results, highlighting a strategic focus on ophthalmology pipeline programs. The company secured a two-tranche financing of $175M in gross proceeds to fund multiple ophthalmology programs through Phase 1 studies.

Key financial metrics for 2024 include:

  • Cash position of $34.6M as of December 31, 2024
  • Additional gross proceeds of $76.4M from March 2025 financing
  • Collaboration revenue of $10M from BI milestone
  • Research and development expenses decreased to $21.1M from $27.2M in 2023
  • Net loss increased to $63.6M compared to $43M in 2023

The company received confirmation that Boehringer will advance SZN-413 toward clinical testing and completed a research collaboration with TCGFB for antibody development targeting TGF-β.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
-
Rhea-AI Summary

Surrozen (NASDAQ: SRZN) announced a strategic shift to focus on ophthalmology programs, supported by an oversubscribed $175 million private placement. The funding will advance multiple eye disease treatments through Phase 1 studies.

The company's two lead candidates for retinopathies are SZN-8141 (Fzd4/VEGF) and SZN-8143 (Fzd4/VEGF/IL-6), targeting conditions like AMD, diabetic retinopathy, and other severe eye diseases. Both compounds have shown promise in preclinical models by stimulating Wnt signaling and promoting normal retinal vessel growth while inhibiting pathological vessel development.

Surrozen will discontinue the development of SZN-043 for severe alcohol-associated hepatitis, despite its safety profile, due to insufficient early clinical benefit signals. The private placement consists of two tranches: an initial $70 million closing around March 26, 2025, and a second $105 million tranche contingent on FDA clearance of the SZN-8141 IND, expected in 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
private placement
-
Rhea-AI Summary

Surrozen (Nasdaq: SRZN), a biotech company focused on targeted therapeutics that activate the Wnt pathway for tissue repair, has announced its participation in two major healthcare investor conferences. CEO Craig Parker will present at the Guggenheim's Inaugural Healthcare Innovation Conference on November 13, 2024, with a fireside chat at 3:00 PM ET, and at the Stifel 2024 Healthcare Conference on November 19, 2024, presenting at 2:25 PM ET. Live audio webcasts will be available through Surrozen's investor website, with recordings archived for later access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
conferences
Rhea-AI Summary

Surrozen reported Q3 2024 financial results with significant progress in its clinical programs. The company received a $10 million milestone payment from Boehringer Ingelheim for SZN-413 development. Key highlights include substantial enrollment in the Phase 1b trial of SZN-043 for severe alcohol-associated hepatitis, with proof-of-concept data expected in H1 2025. The first cohort showed no drug-related serious adverse events and potential clinical benefits. The company reported Q3 revenue of $10 million and a net loss of $1.4 million, with cash position at $31 million as of September 30, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
-
Rhea-AI Summary

Surrozen (SRZN) has announced a strategic research collaboration with TCGFB to develop antibody therapeutics targeting TGF-β for treating idiopathic pulmonary fibrosis (IPF). Under the two-year agreement, Surrozen will provide antibody discovery services while TCGFB will retain all TGF-β product-related intellectual property. In compensation, TCGFB will pay Surrozen up to $6 million plus third-party costs and issue a warrant for up to 3,380,000 shares of TCGFB common stock at $0.0001 per share, subject to vesting conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.78%
Tags
none
-
Rhea-AI Summary

Surrozen (Nasdaq: SRZN) has announced a $10 million milestone payment from Boehringer Ingelheim as part of their collaboration on retinal diseases. Boehringer is advancing the development of SZN-413, a bi-specific antibody targeting Frizzled Class Receptor 4 (Fzd4) mediated Wnt signaling, designed using Surrozen's SWAP™ technology.

SZN-413 offers the potential to restore retinal function in patients with retinal vascular diseases, which affect nearly 150 million people globally. Preclinical data suggest that SZN-413 could stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth, and reduce vascular leakage.

Craig Parker, President and CEO of Surrozen, expressed excitement about Boehringer's decision to proceed with SZN-413's development, highlighting the strong evidence supporting Fzd-4 specific Wnt signaling's role in retinal vasculature.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
none
Rhea-AI Summary

Surrozen (Nasdaq: SRZN) reported Q2 2024 financial results and business updates. Key highlights include:

  • Ongoing enrollment in SZN-043 Phase 1b trial for Severe Alcoholic Hepatitis
  • Presented first-in-human data from SZN-043 Phase 1a trial at EASL
  • Published study on Targeted Protein Degradation technologies
  • Cash position: $37.8 million as of June 30, 2024
  • R&D expenses: $5.3 million, down from $6.9 million in Q2 2023
  • Net loss: $25.3 million, up from $9.4 million in Q2 2023

The company anticipates proof-of-concept data from the SZN-043 Phase 1b trial in H1 2025 and potential nomination of a lead Fzd-4 targeted Wnt agonist development candidate in 2024, which could trigger a $10 million milestone payment from Boehringer Ingelheim.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.14%
Tags
-
Rhea-AI Summary

Surrozen (Nasdaq: SRZN) has published new data in eLife demonstrating the potential of its proprietary SWEETS platform to enhance Wnt signaling. The study highlights the development of two new ASGR-targeted SWEETS bispecific antibodies that improve Wnt-signal activation through a unique protein degradation platform. This innovation offers promising new avenues for treating liver diseases by promoting cell-specific regenerative therapeutics. Additionally, Surrozen released a review in iScience detailing advancements in Wnt-activating technologies, underscoring the significant progress in the field and its potential to address various tissue degenerative diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
Rhea-AI Summary

Surrozen presented preliminary Phase 1a study results of their novel drug SZN-043 at the 2024 European Association for the Study of the Liver (EASL) conference in Milan. This study involved 40 healthy volunteers and 8 liver cirrhosis patients, focusing on dose safety and tolerance. SZN-043 showed potential in increasing Wnt signaling and hepatocyte proliferation, with pharmacodynamic biomarkers confirming target engagement. Mild, transient serum transaminase elevations were noted but resolved without intervention. Current enrollment is ongoing for a Phase 1b study targeting severe alcohol-associated hepatitis, aiming to optimize Wnt pathway modulation for liver regeneration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
Rhea-AI Summary

Surrozen has dosed its first patient in a Phase 1b clinical trial for SZN-043, a bispecific fusion protein targeting ASGR1, aimed at treating severe alcohol-associated hepatitis. This open-label, multi-center trial will involve around 30 patients and assess safety, pharmacokinetics, immunogenicity, and efficacy endpoints like MELD and Lille scores, which are linked to clinical improvement and survival.

CEO Craig Parker highlighted the company's progress and expects proof-of-concept data by the first half of 2025. Previous Phase 1a data indicated SZN-043's safety, tolerability, and beneficial effects on liver function. The trial addresses a significant unmet need, as severe alcohol-associated hepatitis has had no survival improvements for over 50 years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags

FAQ

What is the current stock price of Surrozen (SRZN)?

The current stock price of Surrozen (SRZN) is $10.99 as of April 4, 2025.

What is the market cap of Surrozen (SRZN)?

The market cap of Surrozen (SRZN) is approximately 38.2M.

What is the core focus of Surrozen Inc?

Surrozen is dedicated to discovering and developing regenerative medicines by selectively modulating the Wnt pathway to promote tissue repair, particularly in the liver and eye.

How does Surrozen’s technology work?

The company uses proprietary platforms such as SWEETS and SWAP to engineer tissue-specific bispecific antibodies that activate key Wnt signaling components, thereby enhancing natural regenerative processes.

What therapeutic areas is Surrozen targeting?

Surrozen primarily focuses on severe liver diseases, such as alcohol-associated hepatitis, and ocular conditions related to retinal and corneal degenerations.

How far along are Surrozen’s clinical trials?

Surrozen is in the clinical stage with several drug candidates undergoing early phase trials that assess safety, target engagement, and pharmacodynamic effects in patients and healthy volunteers.

What is the significance of modulating the Wnt pathway?

The Wnt pathway plays a crucial role in tissue development and repair. By modulating this pathway, Surrozen strives to activate the body’s innate repair mechanisms, offering innovative therapeutic options for degenerative diseases.

Who are the founders of Surrozen and what expertise do they bring?

Surrozen was founded by leading scientists with academic backgrounds from elite institutions, including experts in molecular biology and regenerative medicine, who contribute deep research insights into Wnt signaling.

How does Surrozen differentiate itself in the competitive biotech landscape?

Surrozen distinguishes itself through its focused approach on regenerative therapies via targeted Wnt pathway modulation, its innovative antibody engineering platforms, and strategic clinical trial designs that emphasize safety and tissue-specific effects.

What benefits do investors gain from understanding Surrozen’s business model?

Understanding Surrozen’s robust R&D approach, clinical strategy, and its innovative technology platforms provides insights into how the company is addressing significant unmet medical needs, establishing a solid foundation of expertise and authority in regenerative medicine.
Surrozen Inc

Nasdaq:SRZN

SRZN Rankings

SRZN Stock Data

38.15M
3.06M
1.67%
83.56%
4.49%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO